Hemodynamic Evaluation of Glucagon in Symptomatic Heart Disease
Why the study?
Does a 5 mg intravenous bolus of glucagon improve cardiac output in patients with symptomatic heart disease compared to isoproterenol?
Population
26 patients with symptomatic heart disease, evaluated in the cardiac catheterization laboratory and soon…
Comparison
Glucagon 5 mg intravenous bolus vs Isoproterenol
Design
Case_series
Authors
Discussion
Loading...
Member takes
Implication
Glucagon may confer minimal CO gain in advanced HF; leaves open any role versus isoproterenol pending controlled data.
Structured PICO
Does a 5 mg intravenous bolus of glucagon improve cardiac output in patients with symptomatic heart disease compared to isoproterenol?
P
Population
26 patients with symptomatic heart disease (functional class I-IV), evaluated in the cardiac catheterization laboratory and soon after cardiac surgery.
I
Intervention
Glucagon 5 mg intravenous bolus
C
Comparator
Isoproterenol (evaluated in a subset of 8 patients)
O
Outcome
Change in cardiac outputsurrogate
Glucagon is a less effective inotropic agent than isoproterenol and has limited hemodynamic benefit in patients with advanced symptomatic heart disease.
Cite This Study
Armstrong et al. (1971) studied this question.